Palivizumab(pa live ah zoo’ mab)
Synagis
PREGNANCY CATEGORY C
Drug Classes
Antiviral
Monoclonal antibody
Therapeutic Actions
A murine and human monoclonal antibody produced by recombinant DNA technology specific to an antigenic site of the RSV; has neutralizing effects on the RSV.
Indications
-
Prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk for RSV disease
Contraindications and Cautions
-
Contraindicated with allergy to palivizumab or any murine product.
-
Use cautiously with fever (antipyretics should be used to decrease fever before beginning therapy); previous administration of palivizumab (antibodies frequently develop, causing a risk of serious reactions on repeat administration); pregnancy, history of bleeding disorders.
Available Forms
Injection—50 mg/0.5 mL, 100 mg/mL
Dosages
Administer IM only.
Pediatric patients 24 mo and younger
15 mg/kg IM as a single injection, once a month during RSV season, with first dose given before start of RSV season. Give injection preferably in anterolateral aspect of thigh; do not use gluteal muscle because of risk of damaging sciatic nerve. For cardiopulmonary bypass patients, administer a dose as soon as possible following procedure, even if less than 1 month since previous dose.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
